Physician profile
Rachel Liner
NPI 1952878340
$2,656.65
in general payments reported to CMS, 2019-2025
15 companies · $530 in 2025
The $530 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.31 · 2021: $266 · 2022: $490 · 2023: $712 · 2024: $620 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,861.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $986.80 | 2021-2025 | |
| Alkermes, INC. | $305.79 | 2021-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $235.64 | 2022-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $234.35 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $224.60 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $127.26 | 2022-2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $112.67 | 2021-2023 | Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.77 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $76.79 | 2025 | Fanapt |
| Neurocrine Biosciences, INC. | $61.67 | 2025 | |
| Janssen Pharmaceuticals, INC | $52.27 | 2023 | Spravato |
| Bausch Health US, LLC | $52.07 | 2021-2023 | Aplenzin |
| E.R. Squibb & Sons, L.L.C. | $42.70 | 2025 | Cobenfy |
| Neos Therapeutics, LP | $39.31 | 2019 | |
| Sunovion Pharmaceuticals INC. | $17.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Liner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.